rs16969968 — CHRNA5 Asp398Asn

Nicotinic receptor variant strongly associated with heavy smoking, nicotine dependence, and increased lung cancer risk

See your personal result for CHRNA5

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Nicotine Dependence Variant: How One Amino Acid Shapes Addiction Risk

The CHRNA5 gene encodes the alpha-5 subunit of the nicotinic acetylcholine receptor (nAChR), a critical component of the brain's response to nicotine. The rs16969968 variant11 The rs16969968 variant
This SNP is one of the most replicated genetic findings in addiction research, identified independently by multiple genome-wide association studies replaces aspartic acid with asparagine at position 398 of the alpha-5 subunit, fundamentally altering how your brain responds to nicotine. This single amino acid change has emerged as the strongest known genetic risk factor for heavy smoking and nicotine dependence.

The variant sits in the CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15q25, a region that has been consistently associated with smoking quantity22 consistently associated with smoking quantity across populations of European, Asian, African, and Latino ancestry. About 28% of Europeans carry at least one copy of the risk allele, though this frequency varies dramatically by population—only 2% of East Asians carry the A allele, while 15% of South Asians and Latinos do.

The Mechanism

The Asp398Asn substitution alters the structure of the alpha-5 subunit in a critical region called the second intracellular loop, which is highly conserved across species33 highly conserved across species
The aspartic acid at position 398 is preserved in mammals, suggesting strong evolutionary pressure to maintain this amino acid.

Individuals with the AA genotype report significantly lower aversive effects from nicotine44 Individuals with the AA genotype report significantly lower aversive effects from nicotine
In controlled intravenous nicotine administration, AA carriers rated nicotine as less unpleasant (P<5×10⁻⁸), with the effect most pronounced at higher doses, meaning they experience less nausea, dizziness, and discomfort that would normally discourage heavy smoking.

The Evidence

Multiple genome-wide association studies55 genome-wide association studies
The initial 2008 GWAS from three independent research groups all converged on the same chromosomal region identified rs16969968 as the most significant variant associated with smoking quantity. A 2010 meta-analysis pooling data from European populations66 meta-analysis pooling data from European populations
Analyzing over 140,000 individuals found rs16969968 with p=5.57×10⁻⁷² for cigarettes per day found that each A allele increases smoking quantity by approximately 1 cigarette per day, with an odds ratio of 1.3 for being a heavy smoker (≥20 cigarettes/day) versus a light smoker (≤10 cigarettes/day).

In European Americans, each A allele confers OR=1.3 for nicotine dependence. In African Americans, where the allele is rarer (6% frequency), the effect is similar (OR=1.3) when present. Studies in Mexican populations77 Mexican populations
Mexican cohort showed OR=3.12 for heavy smoking in AA carriers versus GG and Middle Eastern populations88 Middle Eastern populations
Palestinian lung cancer cases showed 36.7% A allele frequency versus 17.5% in controls report even stronger associations, though these may reflect population-specific factors.

The variant also affects smoking cessation outcomes99 smoking cessation outcomes
Meta-analyses show AA carriers have delayed time to cessation and lower success rates across multiple cessation interventions. Individuals with the AA genotype quit smoking later in life and have lower success rates with standard cessation interventions. One meta-analysis found the AA genotype is associated with earlier lung cancer diagnosis1010 earlier lung cancer diagnosis
Among lung cancer patients, AA carriers were diagnosed earlier on average in smokers who do develop lung cancer.

Beyond nicotine dependence, the variant shows a dose-dependent association with lung cancer risk1111 a dose-dependent association with lung cancer risk
Each A allele increases lung cancer risk with OR=1.3-1.6, even after adjusting for smoking quantity, with odds ratios ranging from 1.3 to 1.6 per risk allele in different studies. This association persists even after adjusting for smoking quantity, suggesting both a behavioral pathway (more smoking) and potentially a direct biological effect. The variant has also been linked to chronic obstructive pulmonary disease (COPD)1212 chronic obstructive pulmonary disease (COPD)
Mexican cohort showed OR=1.91 for COPD in A allele carriers, another smoking-related disease.

Practical Implications

If you carry one or two copies of the A allele, understand that your brain's natural aversion to nicotine is blunted. You're genetically predisposed to find smoking less unpleasant than others, making it easier to escalate to heavy smoking and harder to quit. This is not a character flaw—it's neurobiology.

For smoking prevention, awareness matters most before starting. Even "social smoking" may escalate more quickly.

For current smokers with the risk genotype, cessation requires more intensive support. Standard approaches like nicotine replacement therapy1313 nicotine replacement therapy
Some evidence suggests NRT efficacy varies by genotype, though this remains under investigation and behavioral counseling may be insufficient.

The lung cancer risk deserves serious attention. Even among smokers, those with the AA genotype develop lung cancer earlier1414 those with the AA genotype develop lung cancer earlier
Meta-analysis of 12,690 smokers found AA carriers diagnosed earlier on average and at younger ages. However, the same study found that quitting smoking reduces lung cancer risk equally1515 quitting smoking reduces lung cancer risk equally
Smoking cessation showed OR=0.48 for lung cancer across all genotypes across all genotypes—the protective effect of quitting does not depend on your CHRNA5 status. Quitting smoking cuts your lung cancer risk in half regardless of your genetic background.

Interactions

The CHRNA5 rs16969968 variant is in strong linkage disequilibrium with rs1051730 in the CHRNA3 gene (r²=1 in Europeans), meaning they are almost always inherited together and their effects are difficult to separate. The 15q25 region also contains CHRNB4 and several other variants (rs588765, rs578776, rs6495309) that show associations with smoking behaviors, though rs16969968 appears to be the primary functional variant based on in vitro studies and cross-population analyses.

The variant's effect on smoking behavior is modified by age of smoking initiation1616 modified by age of smoking initiation
Meta-analysis found the genetic effect is strongest in those who started smoking before age 16, with stronger genetic effects in those who start smoking during adolescence. Environmental factors like childhood adversity and peer smoking also interact with the genotype to influence dependence risk, though the specific mechanisms remain under investigation.

While rs16969968 is the strongest single genetic predictor of nicotine dependence, it explains only a small fraction of overall addiction risk. Smoking behavior is highly polygenic, with dozens of additional variants across the genome contributing smaller effects. Your genotype at this SNP should inform risk assessment and treatment planning, but it does not determine your destiny.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Risk Normal

Typical nicotinic receptor function, standard smoking risk

You carry two copies of the standard aspartic acid (Asp398) variant, meaning your alpha-5 nicotinic receptors function normally. About 64% of Europeans share this genotype. Your brain's natural aversion to nicotine is intact—you experience the full spectrum of unpleasant effects (nausea, dizziness, increased heart rate) that normally limit smoking. If you do smoke, you have the lowest genetic risk for progressing to heavy dependence, and standard cessation methods are most likely to succeed for you. Your lung cancer risk from smoking is still substantial (smoking is the dominant risk factor), but you don't carry the additional genetic vulnerability that AA and AG carriers face.

AG Increased Risk Intermediate

Moderately reduced nicotine aversion, elevated risk for heavy smoking

With one functional copy and one variant copy, your alpha-5 receptors have intermediate function—not as robust as GG carriers, but not as impaired as AA carriers. This creates a dose-dependent effect: you'll find it easier to smoke heavily than GG carriers, but you retain more of the natural brake on nicotine consumption than AA carriers.

Studies show AG heterozygotes occupy a true middle ground, not just averaging the two homozygous groups. Your response to nicotine is moderately altered—you'll experience some aversive effects at high doses, but not as strongly as GG carriers. This explains the intermediate association with smoking quantity and dependence risk.

For cessation, you're between the best and worst prognostic groups. While quitting is harder than for GG carriers, you don't face the severe challenges of AA carriers. Multiple quit attempts are likely needed, and you'll benefit from pharmacotherapy, but success is achievable with appropriate support.

AA High Risk High Risk

Reduced nicotine aversion, significantly elevated risk for heavy smoking and lung cancer

The double dose of the 398N variant reduces alpha-5 receptor function, severely weakening the brain's natural brake on nicotine intake. Studies using controlled intravenous nicotine administration found AA carriers report significantly less nausea, dizziness, and other aversive effects, especially at higher doses. This allows escalation to heavy smoking without the discomfort that would deter others.

Your genetic profile means nicotine dependence is particularly entrenched once it develops. Meta-analyses of smoking cessation trials show AA carriers have the lowest quit rates and longest times to successful cessation across multiple treatment modalities. The protective effect of having fewer functional receptors in the habenulo-interpeduncular pathway—a brain circuit that normally punishes overconsumption—is absent.

The lung cancer risk is substantial and multi-faceted. Part of it is behavioral: you're likely to smoke more heavily and for longer before quitting. But even after adjusting for total smoking exposure, the AA genotype confers additional lung cancer risk (OR=1.3-1.6), suggesting the variant may directly affect lung tissue susceptibility or DNA repair mechanisms, though this remains an active research question.